Patent US3911098A successfully refreshed from Google Patents.
US3911098A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Medicament carrier
Assignee: Wyeth Holdings LLC
•
Filing: 1974-02-11
•
Granted: 1975-10-07
•
Expires: 1994-02-11
Abstract
Abstract A controlled release insert for a living eye consisting of a biologically effective form of pilocarpine and a biologically inert biodegradable carrier consisting essentially of poly(Nacetyl-6-O-(carboxymethyl)-D-glucosamine) gives effective treatment to the human eye for prolonged periods. Other medicaments and other enzymatically degradable forms of poly(Nacetyl-D-glucosamine) may be used for rate controlled release in the eye and other areas.
Inventors
- 👤 Richard Carl Capozza
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 23:24
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/30; A61K47/36; A61K9/00; A61K9/0012; A61K9/0048; A61K9/0051; A61K9/20; A61K9/2004; A61K9/2022; A61K9/205
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
121 words
A METHOD OF DISPENSING AN EYE DRUG OVER A PROLONGED PERIOD OF TINE COMPRISING INSERTING THE CONJUNCTIVAL SAC OF THE EYE A BIOERODIBLE ENZYMATICALLY CLEAVABLE OCCULAR INSERT WHICH IS SHAPED TO CONFORM TO THE CURATURE OF THE EYE AND IS ADAPTED FOR INSERTION AND RETENTION IN THE CONJUNCTIVAL SAC OF THE EYE OF AN EYE DRUG INITIALLY DISPERSED IN AN UNCOATED MATRIX DIRECTLY CONTACTING THE CONJUNCTIVAL SAC OF THE EYE OF AN ENZMATICALLY DEGRADABLE FROM OF POLY(N-ACETYL-D-GLUCOSAMINE) SELECTED FROM THE GROUP CONSISTING OF POLY(N-ACETYL-60-(CARBOXYMETHYL)-D-GLUCOSAMINE, POLY(N-ACETYL-6-0-(2''HYDROXYETHYL)-D-GLUCOSAMINE, AND POLY(N-ACETYL-6-0-(ETHYL)D-GLUCOSAMINE), WHEREBY THE SAID FORM OF POLY(N-ACETYL-DGLUCOSAMINE) IS SLOWLY ENZYMATICALLY DEGRADED BY LYSOZYME IN THE TEARS OVER A PERIOD OF TIME, AND SAID EYE DRUG IS SLOWLY THEREBY RELEASED INTO TEARS, AND CONTACTS THE EYEBALL.
Claim 2
Independent Claim
121 words
A METHOD OF DISPENSING AN EYE DRUG OVER A PROLONGED PERIOD OF TINE COMPRISING INSERTING THE CONJUNCTIVAL SAC OF THE EYE A BIOERODIBLE ENZYMATICALLY CLEAVABLE OCCULAR INSERT WHICH IS SHAPED TO CONFORM TO THE CURATURE OF THE EYE AND IS ADAPTED FOR INSERTION AND RETENTION IN THE CONJUNCTIVAL SAC OF THE EYE OF AN EYE DRUG INITIALLY DISPERSED IN AN UNCOATED MATRIX DIRECTLY CONTACTING THE CONJUNCTIVAL SAC OF THE EYE OF AN ENZMATICALLY DEGRADABLE FROM OF POLY(N-ACETYL-D-GLUCOSAMINE) SELECTED FROM THE GROUP CONSISTING OF POLY(N-ACETYL-60-(CARBOXYMETHYL)-D-GLUCOSAMINE, POLY(N-ACETYL-6-0-(2''HYDROXYETHYL)-D-GLUCOSAMINE, AND POLY(N-ACETYL-6-0-(ETHYL)D-GLUCOSAMINE), WHEREBY THE SAID FORM OF POLY(N-ACETYL-DGLUCOSAMINE) IS SLOWLY ENZYMATICALLY DEGRADED BY LYSOZYME IN THE TEARS OVER A PERIOD OF TIME, AND SAID EYE DRUG IS SLOWLY THEREBY RELEASED INTO TEARS, AND CONTACTS THE EYEBALL.
Claim 3
Dependent Claim
18 words
The method of claim 1 in which the eye drug is pilocarpine free base or a salt thereof.
Claim 4
Dependent Claim
88 words
An enzymatically degradable bioerodible eye drug delivery occular insert device which is shaped to conform to the eye and is adapted for insertion and retention in the conjunctival sac of the eye for administering an eye drug to the eye of a living mammal comprising: an uncoated matrix adapted to directly contact the conjunctival sac of the eye consisting essentially of an enzymatically degradable form of poly(N-acetyl-D-glucosamine) selected from the group consisting of poly(N-acetyl-6-0-(carboxymethyl)-D-glucosamine), poly(N-acetyl-6-0-(2''-hydroxyethyl)-D-glucosamine), and poly(N-acetyl-6-0-(ethyl)-D-glucosamine), and intimately dispersed an at least slightly water soluble eye drug.
Claim 5
Dependent Claim
88 words
An enzymatically degradable bioerodible eye drug delivery occular insert device which is shaped to conform to the eye and is adapted for insertion and retention in the conjunctival sac of the eye for administering an eye drug to the eye of a living mammal comprising: an uncoated matrix adapted to directly contact the conjunctival sac of the eye consisting essentially of an enzymatically degradable form of poly(N-acetyl-D-glucosamine) selected from the group consisting of poly(N-acetyl-6-0-(carboxymethyl)-D-glucosamine), poly(N-acetyl-6-0-(2''-hydroxyethyl)-D-glucosamine), and poly(N-acetyl-6-0-(ethyl)-D-glucosamine), and intimately dispersed an at least slightly water soluble eye drug.
Claim 6
Dependent Claim
19 words
The occular insert of claim 3 in which the eye drug is pilocarpine free base or a salt thereof.
Claim 7
Independent Claim
108 words
A method for dispensing a free base form of an eye drug over a prolonged period of time comprising inserting in the conjunctival sac of the eye a bioerodible enzymatically cleavable occular insert which is shaped to conform to the curvatuve of the eye and is adapted for insertion and retention in the conjunctival sac of the eye of the free base form of an eye drug intimately dispersed in and ionically bound to an enzymatically degradable form of poly(N-acetyl-6-0-(carboxymethyl)-D-glucosamine), whereby the said poly(N-acetyl-6-0-carboxymethyl)-D-glucosamine) is slowly enzymatically degraded over a period of time, and said free base form of said eye drug is slowly thereby released into tears.
Claim 8
Independent Claim
108 words
A method for dispensing a free base form of an eye drug over a prolonged period of time comprising inserting in the conjunctival sac of the eye a bioerodible enzymatically cleavable occular insert which is shaped to conform to the curvatuve of the eye and is adapted for insertion and retention in the conjunctival sac of the eye of the free base form of an eye drug intimately dispersed in and ionically bound to an enzymatically degradable form of poly(N-acetyl-6-0-(carboxymethyl)-D-glucosamine), whereby the said poly(N-acetyl-6-0-carboxymethyl)-D-glucosamine) is slowly enzymatically degraded over a period of time, and said free base form of said eye drug is slowly thereby released into tears.
Claim 9
Dependent Claim
82 words
An enzymatically degradable bioerodible eye drug delivery occular insert device which is shaped to conform to the eye and is adapted for insertion and retention in the conjunctival sac of the eye for administering the free base form of an eye drug to the eye of a living mammal comprising: a matrix consisting essentially of an enzymatically degradable form of poly(N-acetyl-6-0-(carboxymethyl)-D-glucosamine), and intimately dispersed therein and ionically bound thereto, the free base form of an at least slightly water soluble eye drug.
Claim 10
Dependent Claim
82 words
An enzymatically degradable bioerodible eye drug delivery occular insert device which is shaped to conform to the eye and is adapted for insertion and retention in the conjunctival sac of the eye for administering the free base form of an eye drug to the eye of a living mammal comprising: a matrix consisting essentially of an enzymatically degradable form of poly(N-acetyl-6-0-(carboxymethyl)-D-glucosamine), and intimately dispersed therein and ionically bound thereto, the free base form of an at least slightly water soluble eye drug.
References Cited (Backward Citations)
US2040880A
Cited
US2040879A
Cited
US2168374A
Cited
US3632754A
Cited
US3736646A
Cited
US3845201A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1978-10-06 | 1979-04-07 | 1979-10-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1982-10-06 | 1983-04-07 | 1983-10-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1986-10-06 | 1987-04-07 | 1987-10-07 | $7700.00 | Window Closed / Lapsed |